217 related articles for article (PubMed ID: 22161024)
1. Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas.
Fehér LZ; Pocsay G; Krenács L; Zvara A; Bagdi E; Pocsay R; Lukács G; Győry F; Gazdag A; Tarkó E; Puskás LG
Pathol Oncol Res; 2012 Apr; 18(2):449-58. PubMed ID: 22161024
[TBL] [Abstract][Full Text] [Related]
2. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
[TBL] [Abstract][Full Text] [Related]
3. MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.
Sondermann A; Andreghetto FM; Moulatlet AC; da Silva Victor E; de Castro MG; Nunes FD; Brandão LG; Severino P
Clin Exp Metastasis; 2015 Aug; 32(6):521-30. PubMed ID: 26007293
[TBL] [Abstract][Full Text] [Related]
4. MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer.
Dai L; Wang Y; Chen L; Zheng J; Li J; Wu X
World J Surg Oncol; 2017 Jan; 15(1):11. PubMed ID: 28061868
[TBL] [Abstract][Full Text] [Related]
5. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A
Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.
Yip L; Kelly L; Shuai Y; Armstrong MJ; Nikiforov YE; Carty SE; Nikiforova MN
Ann Surg Oncol; 2011 Jul; 18(7):2035-41. PubMed ID: 21537871
[TBL] [Abstract][Full Text] [Related]
7. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
8. Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines.
Finn S; Smyth P; O'Regan E; Cahill S; Toner M; Timon C; Flavin R; O'Leary J; Sheils O
Arch Pathol Lab Med; 2007 Jan; 131(1):65-73. PubMed ID: 17227125
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker.
Wreesmann VB; Sieczka EM; Socci ND; Hezel M; Belbin TJ; Childs G; Patel SG; Patel KN; Tallini G; Prystowsky M; Shaha AR; Kraus D; Shah JP; Rao PH; Ghossein R; Singh B
Cancer Res; 2004 Jun; 64(11):3780-9. PubMed ID: 15172984
[TBL] [Abstract][Full Text] [Related]
10. Integrated DNA and RNA sequencing reveals targetable alterations in metastatic pediatric papillary thyroid carcinoma.
Potter SL; Reuther J; Chandramohan R; Gandhi I; Hollingsworth F; Sayeed H; Voicu H; Kakkar N; Baksi KS; Sarabia SF; Lopez ME; Chelius DC; Athanassaki ID; Mahajan P; Venkatramani R; Quintanilla NM; Lopez-Terrada DH; Roy A; Parsons DW
Pediatr Blood Cancer; 2021 Jan; 68(1):e28741. PubMed ID: 33009870
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
[TBL] [Abstract][Full Text] [Related]
12. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
[TBL] [Abstract][Full Text] [Related]
14. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
[TBL] [Abstract][Full Text] [Related]
15. Oncogene profile of papillary thyroid carcinoma.
Sugg SL; Ezzat S; Zheng L; Freeman JL; Rosen IB; Asa SL
Surgery; 1999 Jan; 125(1):46-52. PubMed ID: 9889797
[TBL] [Abstract][Full Text] [Related]
16. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
17. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
18. ENHANCED BETA-CATENIN EXPRESSION IS ASSOCIATED WITH RECURRENCE OF PAPILLARY THYROID CARCINOMA.
Kordestani Z; Sanjari M; Safavi M; Mashrouteh M; Asadikaram G; Abadi MFS; Mirzazadeh A
Endocr Pract; 2018 May; 24(5):411-418. PubMed ID: 29498921
[TBL] [Abstract][Full Text] [Related]
19. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
[TBL] [Abstract][Full Text] [Related]
20. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
